Search - tctmd.com

Displaying 1 - 20 of 24

Sort: Relevancy | Date

News Daily News

Metoclopramide May Mute Morphine’s Hampering of Ticagrelor Efficacy

Caitlin E. Cox

November 28, 2018

News Conference News AHA 2018

Very EARLY Invasive Angiography in NSTE ACS Patients Reduces Risk of Recurrent Ischemia

Michael O'Riordan

November 11, 2018

News Daily News

SORT-OUT IX: Statistical Mix-up Turns Trial’s Primary Endpoint Around

Michael O'Riordan

November 06, 2018

News Daily News

Gender Gap May Be Narrowing in ACS Patients, With Mortality Advantage for Elderly Women

L.A. McKeown

October 12, 2018

Presentation TCT Abstracts Posters 2018

A comparative study of one year all-cause mortality in ST Elevation myocardial infarction patients treated with prasugrel and ticagrelor after primary percutaneous coronary intervention

Presenter: Ayush Khurana

September 25, 2018

Presentation TCT 2018

How Strong are the Pharmacodynamic Data and Clinical Evidence for Crushed Ticagrelor and Prasugrel?

Presenter: John A. Bittl, C. Michael Gibson, Dimitrios Alexopoulos

September 23, 2018

Polymer-Free BioFreedom Stent as Safe as Orsiro, but Not as Effective

News Conference News TCT 2018

CORRECTION: Polymer-Free BioFreedom Stent Faces Off Against Orsiro

Michael O'Riordan

September 22, 2018

Presentation TCT 2018

TROPICAL-ACS: Platelet Reactivity and Clinical Outcomes in Acute Coronary Syndrome Patients Treated With Prasugrel and Clopidogrel

Presenter: Jonathan M. Hill, E. Magnus Ohman, Dániel Aradi

September 22, 2018

News Conference News ESC 2018

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

Shelley Wood

August 28, 2018

News Daily News

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Michael O'Riordan

July 31, 2018

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

News Daily News

Platelet Reactivity Linked With Ischemic Stroke Risk Post-DES Implantation: ADAPT-DES Substudy

Yael L. Maxwell

June 08, 2018

News Conference News EuroPCR 2018

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

Yael L. Maxwell

May 30, 2018

News Daily News

One in Five ACS Patients Does Not Fill P2Y12 Inhibitor Prescription After PCI

Michael O'Riordan

May 21, 2018

News Daily News

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Michael O'Riordan

May 01, 2018

News Conference News SCAI 2018

Doctors, Risk Tools Often at Odds When Assessing Risks in Patients With A-fib Undergoing PCI

Todd Neale

April 27, 2018

News Daily News

Another Observational Study Supports Role for Genotype-Guided Antiplatelet Choices Post-PCI

Yael L. Maxwell

April 04, 2018

News Conference News ACC 2018

PHARMCLO: Biggest Genotyping Trial to Date Suggests Better Outcomes After ACS, With Caveats

Yael L. Maxwell

March 14, 2018

News Conference News ACC 2018

Genetic Testing Influences Post-PCI Antiplatelet Prescriptions, but Other Factors Also Play a Role

Yael L. Maxwell

March 11, 2018

News Conference News ACC 2018

Reducing Co-payments for P2Y12 Inhibitors Upped Ticagrelor Use but Didn’t Budge MACE: ARTEMIS

Caitlin E. Cox

March 11, 2018

Advertisement

Metoclopramide May Mute Morphine’s Hampering of Ticagrelor Efficacy

Very EARLY Invasive Angiography in NSTE ACS Patients Reduces Risk of Recurrent Ischemia

SORT-OUT IX: Statistical Mix-up Turns Trial’s Primary Endpoint Around

Gender Gap May Be Narrowing in ACS Patients, With Mortality Advantage for Elderly Women

A comparative study of one year all-cause mortality in ST Elevation myocardial infarction patients treated with prasugrel and ticagrelor after primary percutaneous coronary intervention

How Strong are the Pharmacodynamic Data and Clinical Evidence for Crushed Ticagrelor and Prasugrel?

CORRECTION: Polymer-Free BioFreedom Stent Faces Off Against Orsiro

TROPICAL-ACS: Platelet Reactivity and Clinical Outcomes in Acute Coronary Syndrome Patients Treated With Prasugrel and Clopidogrel

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Platelet Reactivity Linked With Ischemic Stroke Risk Post-DES Implantation: ADAPT-DES Substudy

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

One in Five ACS Patients Does Not Fill P2Y12 Inhibitor Prescription After PCI

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Doctors, Risk Tools Often at Odds When Assessing Risks in Patients With A-fib Undergoing PCI

Another Observational Study Supports Role for Genotype-Guided Antiplatelet Choices Post-PCI

PHARMCLO: Biggest Genotyping Trial to Date Suggests Better Outcomes After ACS, With Caveats

Genetic Testing Influences Post-PCI Antiplatelet Prescriptions, but Other Factors Also Play a Role

Reducing Co-payments for P2Y12 Inhibitors Upped Ticagrelor Use but Didn’t Budge MACE: ARTEMIS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content